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The airway epithelium functions as a barrier and front line of host defense in the lung. Apoptosis or programmed cell death
can be elicited in the epithelium as a response to viral infection, exposure to allergen or to environmental toxins, or to drugs.
While apoptosis can be induced via activation of death receptors on the cell surface or by disruption of mitochondrial polarity,
epithelialcellscomparedtoinﬂammatorycellsaremoreresistanttoapoptoticstimuli.Thispaperfocusesontheresponseofairway
epithelium to apoptosis in the normal state, apoptosis as a potential regulator of the number and types of epithelial cells in the
airway, and the contribution of epithelial cell apoptosis in important airways diseases.
1.Introduction
The airway epithelium is the ﬁrst barrier and ﬁrst line of
host defense in the airway. Formerly considered a more inert
barrier that “kept the outside out and the inside in,” it is
now clear that epithelial cells participate in host defense
and inﬂammation. The networks in which the epithelium
participatesindeedcanorchestrateeitherorboth,depending
on whether these networks are activated normally or not.
A more classical view of epithelial responses to injury
and inﬂammation emphasized the ability of the epithelium
to respond to insults by secretion of water and mucous
into the airways and mediator secretion (e.g., cytokines
and chemokines) into the local environment and into the
circulation. In this view, the epithelial layer responded to
physical injury by a process that included, in order, phago-
cytic clearance of damaged cells and material, proliferation
of new epithelial cells from surviving nearby stem cells,
diﬀerentiation(phenotypeshiftingmaybepreferred)tonew,
required cell subtypes such as ciliated and mucous (goblet)
cells, and restoration of barrier function [1]. Over the past
two decades, it has become clear that proper protection and
repair of the airway mucosa against sustained damage may
also depend on the processes that control programmed cell
death, that is, apoptosis.
Apoptosis is a tightly regulated process of nonnecrotic
cell death that is critical for normal tissue and organ
homeostasis. Cells undergo apoptosis through the activation
of carefully regulated pathways that lead to their orderly
shutdown and removal. In this paper, I examine the occur-
rence and function of apoptosis both in the normal airway
epithelium and in the epithelium in several airways diseases.
In the context of these diseases, epithelial cell apoptosis
may be either a compensatory response, a pathogenetic con-
sequence, or both. I limit this paper to discussion of cen-
tral airways (tracheal and bronchial) epithelial cells with
appropriate mention of small airway and alveolar epithelial
cellswherewarrantedandtotheprocessofapoptosis,leaving
aside other mechanisms of cell death such as necrosis and
autophagy.
2.Studyingthe AirwayEpitheliuminApoptosis
In examining apoptosis in the airway epithelium, it should
be noted that several methods examine epithelium both in
situ and in culture. Each of course has its limitations and
strengths.
Collection of full-circumference airways is useful to
examine epithelial morphology, damage, proliferation, and
apoptosis in a setting that preserves the architecture of2 Journal of Allergy
the full-thickness airway. Various morphologic and his-
tologic strategies, including antibody labeling or electron
microscopy, can be used. This method is limited to the
s t u d yo fs p e c i m e n sc o l l e c t e de i t h e rb yl u n gr e s e c t i o no r
at autopsy. Endobronchial biopsies can be obtained more
easily (compared to open lung biopsy or autopsy) and allow
for both one-time and, in some special cases, repeated
sampling of airways, but crush artifact may limit the ability
to interpret morphological changes in the mucosal layer
[2]. Endobronchial brushings can collect epithelial cells
for subsequent culture or harvest of RNA but provide no
information about morphology.
The culture of airway epithelial cells likewise can be
useful to elucidate mechanisms but has limitations. Primary
cells typically have been grown in submersion culture, a
method used for over four decades in many laboratories;
these have a monomorphic appearance that resemble basal
airway epithelial cells. Submersion culture can generate
experiments quickly to test hypotheses and mechanisms but
do not provide information about the morphology of ep-
ithelial subtypes and thus raises a concern about how
applicable the results from these experiments are to the in
situ state. Epithelial cells can be grown in an “air-liq-uid
interface” (ALI), a more recent culture method that permits
diﬀerentiation (a better term may be “phenotype shifting”)
over a period of 2 to 5 weeks of culture into basal, columnar,
and goblet cells that resembles a native epithelium [3, 4].
While more technically demanding, such cultures provide
additional information about morphology and potential
interactions between the epithelial subtypes. As with sub-
m e r s i o nc u l t u r e ,d a t af r o mc e l l sg r o w ni nA L Ic u l t u r em a y
not be fully applicable to the in situ airway. Finally, a
number of airway epithelial cell lines have been generated
over the past three decades. Several of these, such as the
16HBE14o-and1HAEo-celllinesthatareSV40transformed
from normal cells [5, 6] and the A549 lung adenocarcinoma
cell line [7], have been popular in studies of epithelial cell
apoptosis due to the ease of culture and the reproducibility
of the cells over a number of passages. However, whether
SV40 transformed or derived from cancer cells, it should be
acknowledged that proliferation and apoptosis pathways and
regulators may well be diﬀerent in these cells versus primary
cellsandthatcellsinculturemaynotbehaveasepithelialcells
in situ in their unique microenvironment.
One potential issue with the culture of epithelial cells
is that (done properly) there are no other cell types in the
culture system. While the response of pure epithelial cells
to a stimulus is useful in reductionist-style experiments, ex-
amining interactions between diﬀerent cell types may be just
as important. To meet this concern, dual-culture systems
grow epithelial cells on a ﬁlter either in submersion or in
air-liquid interface suspended above a second cell type (e.g.,
ﬁbroblasts) grown either on the underside of the ﬁlter or
in the bottom of the culture container. Other dual-culture
systems expose epithelial cells to bacteria (e.g., coculture
or addition of Pseudomonas aeruginosa), with subsequent
examination of apoptotic markers. Such biculture systems
permit a limited examination of inﬂuences of these cells on
epithelial cell apoptosis, or vice-versa.
Understanding the role of apoptosis in airway epithelium
and interpreting the many studies done also require a clear
awareness of the usefulness and limitations of each method
ofanalysis.Arecountingofapoptosismethodsiswellbeyond
this paper but two recent reviews outlining guidelines for
the use and interpretation of assays to analyze cell death
(apoptosis, autophagy, and necrosis) are useful reminders of
the signiﬁcant methodological and analytical issues [8, 9].
3.ApoptosisMechanisms
Apoptosis is the orchestration of cell death by highly con-
served genes in eukaryotes [10–13] that permits the removal
of damaged or unneeded cells from tissue without releasing
cellular contents that would otherwise damage surrounding
cells or elicit an inﬂammatory response. It is tightly and
carefully regulated in normal circumstances but may be
inappropriately activated or suppressed in diverse disease
states [12]. In contrast to cell necrosis, the principal features
of apoptosis include shrinkage of the cell, condensation
of the nucleus, DNA fragmentation, fragmentation of the
cell cytoskeleton, and eventual formation of an apoptotic
body that is either shed or phagocytized [14]. Several
reviews examine general mechanisms of apoptosis and are
recommended [9, 12, 15–17].
Multiple signals that initiate apoptosis including death
receptors, cytokines, heat and oxidative stress, and ionizing
radiation link to a signaling cascade of serine proteases
known as caspases. These proteases are constitutively ex-
pressedasinactivezymogensthatarecleavedwhenactivated.
Upstream caspases (e.g., caspase-8) work to collect receptor-
mediated signals and initiate the death cascade, whereas
downstream caspases (e.g., caspase-3) act upon targets in the
both cell nucleus and cytosol (Figure 1).
Two distinct pathways exist for caspase activation. The
ﬁrst, type I, termed the “extrinsic” pathway because it is
activated by extracellular signals, involves ligation of cell sur-
face death receptors [11, 13, 18, 19], members of the tumor
necrosis factor (TNF) superfamily, such as CD95 (also Fas
or APO-1) [14, 20], TNFR1, DR3, DR4, DR5, DR6, EDAR,
and p75NTR [21]. Each contains an exclusive, 80 amino-
acid long domain, the “death domain,” essential to induce
apoptosis [13, 21, 22]. When ligated, the receptors form
homotrimers that recruit molecules into a “death domain.”
Activation of these domains (e.g., interaction of Fas with
Fas-associated death domain or FADD, or the interaction of
TNFR1 with the TNR-receptor-associated death domain or
TRADD) leads to formation of a death-inducing signaling
complex(DISC)[23,24]andsubsequentlycaspaseactivation
[25, 26].
The cognate death receptor ligands generally are com-
prised of a C-terminal extracellular portion which interacts
with the death receptor, a transmembrane region, and an
N-terminal domain. The best-described ligands are CD95L
(FasL), that bind CD95, TNF-α, and the TNF-related apop-
tosis-inducing ligand (TRAIL).
CD95L is perhaps the best-characterized death receptor
ligand. It was originally considered to be expressed mostlyJournal of Allergy 3
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Figure 1: Extrinsic (receptor-mediated) and intrinsic (stress or oxidant-mediated) pathways that initiate apoptosis. Receptors such as CD95
and DR4 initiate apoptosis by interacting with death domain proteins such as FADD or TRADD, leading to the cleavage and activation of
procaspase-8 with subsequent activation of downstream caspases and the initiation of the nuclear and cytoplasmic events that comprise
apoptosis. In the intrinsic pathway, stress or oxidant-mediated injury leads to activation of proapoptotic BH3 proteins such as BAX or BAK;
these then induce disruption of mitochondrial polarity leading to the release of cytochrome c, which binds APAF-1 in the “apoptosome,”
leading to cleavage and activation of caspase-9. This then leads to downstream caspase activation. Cross-talk from the extrinsic pathway via
the truncation of Bid (to t-Bid) can also elicit disruptions of mitochondrial polarity so that both pathways may be activated. Mitochondrial
integrity is regulated by a series of related antiapoptotic (Bcl-2, Bcl-xL) and proapoptotic (Bad, Bax, Bak) proteins. The downstream caspase
cascade can be inhibited by inhibitors of apoptosis such as XIAP, cIAP-1, and cIAP-2.
by hematopoietic cells such as lymphocytes and dendritic
cells, but also is demonstrated in immune-privileged sites
and in states of chronic inﬂammation, and not only mediates
cell death but also serves as an eﬀector molecule to estab-
lish immune privilege and enhance cell survival [21, 27].
Originally described as a transmembrane molecule, CD95L
now is recognized to have a soluble variant cleaved from
the cell surface by metalloproteases [28, 29]; alternately,
it is packaged with other lysosomal proteins in lysosomes
and transported to the plasma membrane where it is
then released into the external environment [27]. Soluble
CD95L binds its receptor with the same eﬃciency as the
transmembrane form.
TNF-α has complex eﬀects on airway epithelial cells and
may both elicit and oppose apoptosis depending on context.
It is a “proinﬂammatory” cytokine that induces several
eﬀects in airway epithelium, such as (of many examples) the
expression of the ICAM-1 adhesion molecule [30–32]a n d
IL-6 and IL-8 [33–35]. TNF-α binds two distinct receptors:
TNFR1 and TNFR2 [36]. The former is responsible for the
cytotoxic, including apoptotic, eﬀects of TNF-α,w h e r e a s
both receptors can interact with a series of adaptor proteins,
the TNF-associated factors (TRAF). TRAF2 but not TRAF1
can initiate activation of the NF-κB signaling cascade [37]
to elicit IL-8 secretion [33, 34]. Disrupting NF-κB signaling
can enhance TNF-α-mediated apoptosis; likewise, activating
NF-κB signaling can suppress TNF-α-mediated apoptosis
[38]. Thus, TNF-α-mediated cell death and inﬂammation
exist in a balance that can be perturbed by several pathways.
TRAIL also is a member of the TNF superfamily [39].
TRAIL is a type II membrane protein that induces apoptosis
in a variety of target cells. In some cell types, TRAIL
binding to the death receptors DR4, DR5, and/or DcR2
may also activate the transcription factor NFκB, leading
to transcription of genes that actually antagonize death
signaling pathways and promote inﬂammation [40, 41].
A second pathway that elicits apoptosis, type II or
the “intrinsic pathway,” is activated not by receptors but4 Journal of Allergy
by stressors such as oxidative stress, DNA damage, and
starvation [14, 42] and has as its deﬁning characteristic a
requirement for increased mitochondrial permeability that
then releases cytochrome c. Cytochrome c combines with
APAF-1 to cleave and activate procaspase-9 in a complex
termed the “apoptosome” [19, 43, 44]. The mitochondria
thus may serve as a “central apoptotic executioner” to inte-
grate multiple, diverse internal signals that indicate cellular
damage. Activation of either pathway leads to cleavage and
activation of common pathway caspases such as caspase-3
(Figure 1) and commits the cell to an apoptotic death [14].
Both pathways are regulated by a family of proteins
known as the inhibitors of apoptosis (IAPs). Most of these
suppress caspases either by binding the active catalytic site
of eﬀector caspases, by preventing dimerization of caspase-
9, by sequestering mitochondrial proteins, or by stimulat-
ing degradation and ubiquitination of caspases [45]. The
Bcl-2 family of prot1ns also heavily regulates the type II
mitochondrial pathway. These proteins have a conserved
Bcl2 homology domain that allows the family member to
join to other members. The prosurvival members of the
family (Bcl2, Bcl-XL, BclW, MCL1, A1, and BOO/DIVA)
have multiple Bcl2 homology domains [14, 46]. In contrast,
the proapoptotic protiens have a diﬀerent number of Bcl2
homology domains: BAX and BAK, for example, each
has three such domains, and both function to increase
mitochondrial membrane permeability and thereby release
cytochrome c [14, 47]. Other proapoptotic Bcl proteins
(BIM, BID, PUMA) have an alternate Bcl2 homology 3
(BH3) domain that binds to and inhibits prosurvival Bcl2
family members, thus releasing BAX and BAK [48, 49]. A
balance between prosurvival and proapoptotic Bcl2 proteins
determines life or death, and each family member may be
activated or suppressed diﬀerently depending on the cell
stress or death activator.
4. Apoptosis Receptors and Receptor
LigandsinEpithelialCells
One death receptor clearly identiﬁed on airway epithelial
cells is CD95. Our laboratory group ﬁrst demonstrated this
deathreceptorandtheexpressionofitscorrespondingligand
CD95L (FasL), in primary central airway epithelial cells and
celllinesinsubmersioncultureandinairwayscollectedfrom
lung resection surgery [20]( Figure 2). Ligation of CD95
using the Ch11 antibody that cross-links the receptor acti-
vatescaspasepathwaysandelicitscelldeath[20,50,51].Both
CD95 and CD95L subsequently have been demonstrated in
airwayepitheliuminpatientswithcysticﬁbrosis[52];CD95L
expression is markedly increased in these airways, which was
also demonstrated in an epithelial cell line, HTEC, with a
CF genotype. These observations, including that the CD95
receptor is functional, have since been replicated; one such
study suggests that epithelial cell apoptosis induced by CD95
ligation may be less important than that induced by TNF-α
[53]. CD95 has been demonstrated in small airway epithelial
cells (SAEC) in culture, and when compared to epithelial
cells collected from larger, proximal airways, SAEC is more
sensitive to CD95 ligation with a recombinant, soluble FasL
[54]. CD95 expression also has been demonstrated in type II
alveolar epithelial cells in humans and other mammals [55–
58] and may be involved in fetal lung development [59].
CD95L expression in human airway epithelium may
serve, as it is postulated to serve in other immune privileged
sites such as retina, brain, and testis, as an “immune barrier”
[20, 60]. Airway epithelial FasL levels are increased in pa-
tients with severe asthma after steroid treatment, although
it is possible that this increase in FasL levels reﬂects a
more severe stage of disease [61]. One recent paper dem-
onstrates that transmembrane FasL on epithelial cells is
cleaved by matrix metalloproteinase (MMP)-7; this in turn
is upregulated by the Th2-associated cytokine IL-13 [62].
As this MMP is increased in asthmatic airway epithelium,
this study suggests a mechanism whereby increased CD95L
in asthmatic airways might serve either to reestablish the
immune barrier (by activating apoptosis in inﬂammatory
cells) or to perpetuate mucosal damage (by activating apop-
tosis in epithelial cells).
These studies, taken together, make clear that both CD95
anditsligandarepresentandfunctionalinairwayepithelium
both in vivo and in culture models and may be increased in
expression in asthmatic epithelium.
As noted previously, TNF-α binds two distinct receptors:
TNFR1 (also p60 TNFR) and TNFR2 (p80 TNFR). The for-
mer has an 80 amino-acid cystein-rich domain in its extra-
cellular domain that can contain either a death domain, a
TRAF binding domain, or a decoy domain [63]. The death
domain interacts with the TNFR-associated death domain
protein (TRADD), which in turn interacts with the Fas-
associateddeathdomainprotein(FADD)toactivatecaspase-
8[ 37, 64]. In this way, TNFR1 shares the same downstream
signaling pathway and machinery as CD95.
Remarkably few studies have been done to examine
TNFR-pathway-driven apoptosis in airway epithelial cells
and cell lines. Mitola et al. examined the eﬀect of sputum
sol phase collected from a cohort of patients with cystic
ﬁbrosis on apoptosis of primary human bronchial epithelial
cells [65]. The TNF pathway was activated, but a direct link
to TNF-α in the sputum sol phase was not demonstrated.
Another recent study demonstrated that TNF-α stimulated
caspase-3 activation and IL-8 expression in primary air-
way epithelial cells via phosphorylation of p38 mitogen-
activated protein kinase (MAPK), an eﬀected potentiated by
concurrent exposure to nontypeable Haemophilus inﬂuenzae
[66]. Activation of NF-κB pathways and involvement of
TRADD were not examined in this study. Other stress-
activated protein kinases such as c-Jun N-terminal kinase
(JNK) are well recognized to suppress TNF-α-stimulated
apoptosis (reviewed in [67]), but this has not been studied
in airway epithelium.
In addition to receptor-driven activation that directly
initiates apoptosis, TNFR activation may modulate apop-
tosis by indirect mechanisms, in addition to any survival
signals and inﬂammatory signals delivered by its activation
of the NF-κB signaling pathway. For example, treatment
with TNF-α in primary proximal airway epithelial cells
enhances subsequent apoptosis elicited by exposure toJournal of Allergy 5
(a) (b)
Figure 2: Expression of the CD95 receptor (a) and its ligand, CD95L (b), in a normal human airway using an immunoperoxidase method.
Both basal and columnar cells stain for receptor and ligand (brown, with hematoxylin counter label). The appropriate controls (not shown
here) for substitution of primary antibody do not label. Original magniﬁcation, 200x. From [20].
CD95L [54], demonstrating a clear potential interaction in
these pathways. TNF-α treatment in the H441 and A549
lung adenocarcinoma lines elicits gene expression of both
TRAF1 and cIAP2 and that both were increased in the lungs
ofinfantswithfatalbronchopulmonarydysplasia[68].These
signaling interactions are complex but suggest potential
therapeutic strategies in manipulating death versus survival
pathways in TNFR-mediated signaling.
The expression of TRAIL, a ligand for several death re-
ceptors, is increased, as demonstrated by immunohisto-
chemical labeling, in the epithelium of endobronchial biop-
sies collected from asthmatic airways [69]. TRAIL expression
is also noted in Th2 cells [70]. However, in contrast to the
clear presence of CD95, no published studies have demon-
strated the presence of potential partner death receptors,
including DcR1, DcR2, DR4, or DR5, in airway epithelium
in normal human airways, though one paper demonstrates
both DR4 and DR5 in guinea pig airways [71], and one
paper demonstrated the R1 and R2 receptors for TRAIL in
nonbronchoscopically obtained epithelial cells from children
suﬀering from RSV infection accompanied by respiratory
failureandmechanicalventilation[72].TRAILmaybindone
of the TNFRs that are induced during diseases processes,
which then may activate cell death pathways via relatively
novel signals that include phosphorylation of p38-MAPK
[66]. The relative expression of and signaling pathways
connected to these receptors and the circumstances of their
expression in health and in airways diseases in human airway
mucosa require further exploration.
5. Apoptosis inNormal AirwayEpithelium
Apoptosis has an important, beneﬁcial regulatory role in the
normal airway epithelium. As noted previously, it provides
a mechanism to remove damaged cells without provoking
an inﬂammatory response. An additional beneﬁcial role
is, along with cell proliferation, regulating the number of
epithelial cells. The cell cycle rate in resting mammalian large
airway epithelium in situ, expressed as the proportion of
dividing cells counted in thymidine incorporation assays, is
<1% [73, 74]. Corresponding rates of apoptosis, as judged
by labeling for an apoptosis marker (e.g., TUNEL), are also
low in normal mouse [75]a n dh u m a n[ 76, 77]a i r w a y
mucosa. Exogenous and endogenous signals that stimulate
proliferation may also stimulate apoptotic pathways so as
to counter survival signals and thus maintain epithelial cell
homeostasis [78].
One potential problem in measuring rates of apoptosis
in airway epithelium, either normal or in disease states, is
that dying epithelial cells may slough into the airway lumen
prior to the demonstration of classic apoptosis markers
by morphological methods. Detachment followed by cell
death, termed anoikis (for a review see [79]), may lead to
underestimation of rates of apoptosis in airway epithelium,
thoughothermarkersofdamage,suchasfocalgaps,denuda-
tion, or expression of markers such as the epithelial growth
factor receptor or c-erbB-2 [80, 81], are still present. Dead
(apoptotic or necrotic) epithelial cells in sputum degrade
rapidly and may not be recognized or counted. One recent
study collected sputum from marathon runners and then
examined the number of apoptotic epithelial cells by TUNEL
labeling followed by histologic examination. Their study
demonstrated an ability to detect a signiﬁcant number of
positive cells [82]. This study suggests technical feasibility to
examinethesputum.Anotherstudyexaminedtheexpression
of DAP kinase,n o t e dt oh a v ear o l ei nT N F - α,F a s ,a n d
interferon-gamma- (IFN-γ-) induced apoptosis [83, 84]a n d
in oncogenic transformation of cells [85], and in epithelial
cellspresentinthesputumofacohortofcancerpatients,and
correlated this to changes in expression in airway epithelium
collectedbybronchialbrushing[86].Thisstudysuggeststhat
surrogate markers might be used to examine the presence
of apoptotic epithelial cells and to examine activation or
expression of pathways that might initiate cell death.
Another diﬃculty of detecting apoptotic cells in either
normal or diseased tissue underscores the purpose of
apoptosis: that of rapid, eﬃcient execution, and clearance
of damaged cells (now apoptotic bodies) so as to prevent6 Journal of Allergy
aggravation of inﬂammation [87, 88]. Removal of apoptotic
epithelial cells in the airway (whether by shedding into the
lumen or by phagocytosis) may be accompanied soon after
by proliferation and/or phenotype shifting of neighboring
cells to replace the lost cells. Indeed, both apoptosis and
proliferation may be increased in diseases such as asthma
[53, 89]. Demonstration of signiﬁcant numbers of apoptotic
cellsmightnotonlysuggestsigniﬁcantinjuryandresponseto
injury, but may also suggest a defect in clearance of apoptotic
cells(reviewedin[90]),aﬁndingthat,forexample,maybeof
importance in emphysema [87]. Accumulation of apoptotic
bodies may exert direct inhibitory or damaging eﬀects on
neighboring cells and may lead to continued inﬂammation
[15], though this has yet to be speciﬁcally demonstrated in
airway mucosa.
Therefore, particularly in disease states, the true propor-
tion of apoptotic cells may be underestimated by morpho-
logical methods that depend on the continued presence of
the dead or dying cell.
Since airway epithelial cells have the CD95 receptor, it
follows that ligating that receptor should activate pathways
that lead to cell death. Both in primary cells and in cell lines,
this is clearly true [20, 50]. However, of interest is not that
epithelial cells die in response to CD95 ligation, but that
in most culture systems using primary cells collected from
normal subjects or in cell lines, maximal activation of this
receptor elicits death in only 10–20% of the cells present over
a 24 to 48hr time period. This is in sharp contrast to studies
done in lymphocytes, eosinophils, and other inﬂammatory
cells,inwhichCD95ligationgenerallyelicits>80%celldeath
in less than 8hr (as several of many examples, see [64, 91,
92]).Onemightask,ifepithelialcellsexpressbothligandand
receptor, why one epithelial cell does not kill its neighbor?
The answer may be that epithelial cells, at least under
normal conditions in the airway (or in standard culture), are
relatively resistant to CD95-induced death signaling, either
by an inability to cluster and activate the receptor trimer
required for FADD activation or further along the signaling
pathway. This further suggests two possibilities. The ﬁrst is
that either a second “costimulatory” signal is required for
maximal killing. No such signal has been demonstrated in
airway epithelium, but signals that sensitize cells to death
receptor stimulation are seen in other systems. For example,
IFN-γ and TNF-α sensitize human endometrial stromal
cells, normally apoptosis resistant, to CD95-mediated cell
death due to an upregulation of CD95 expression [93],
and interleukin (IL)-10 protects mouse intestinal epithelial
cells from Fas-induced apoptosis by downregulating Fas
expression and regulating the expression of death domain
components [94].
A second possibility is that a change in the environment
elicits a reconﬁguration of the receptor that makes it more
amenable to activation. Data to support such a hypothesis in
airwaysarelacking,but,inothersystems,itisclearthatCD95
receptor regulation in turn regulates the ability to switch
on apoptosis. For example, expressing a mutant CD95 that
lacks a death domain, and therefore cannot initiate DISC
formation, blocks apoptosis ordinarily elicited with an anti-
CD95 antibody, even as the receptor trimers aggregate [95].
Expression of the cellular FLICE-like inhibitory protein (c-
FLIP), a component of the death-eﬀector domain, can either
inhibit or activate both CD95 and other death receptors
dependent on context (reviewed in [24]), but this regulator
has yet to be described in airway epithelium.
In the normal airway epithelium then it is clear that
apoptosis, like proliferation, is tightly regulated to the point
t h a ti ti su n c o m m o n l ys e e na sb e s ta sc a nb ed e t e c t e dw i t h
currentmethods.Epithelialcellscanrespondtodeathstimuli
in the culture environment but even then there is relative
resistance. Understanding the “default” setting of “no death”
may help us to understand compensatory responses and
disease states in which apoptosis clearly is activated.
6.Apoptosis as aMechanismtoMaintain
EpithelialCellHomeostasis
Both in disease states such as asthma and COPD and
after various environmental exposures, signiﬁcant goblet cell
hyperplasia (GCH) may be seen [96–98]i na i r w a ym u c o s a .
Cytokines such as IL-13 and IL-4 can stimulate phenotype
shifting of large airway basal [99] or small airway epithelial
(Clara)cells[100]tomucoidcellsbyinducingmucinexpres-
sion [99–104]; two separate reports suggest that ciliated
cells may also shift to a mucoid phenotype under certain
conditions[105,106].Thebacterialwallinﬂammatoryfactor
lipopolysaccharide(LPS)alsocaninduceGCHincellculture
models of epithelial cell phenotype shifting [107, 108]a s
can irritants such as cigarette smoke [109]. There may also
be an increase in the total number of epithelial cells over
time with most of the new cells manifesting a mucoid
phenotype [110]. Resolution of goblet cell hyperplasia is
associated with downregulation of mucin protein expression
and either phenotype shifting of these cells to a Clara or
serous cell phenotype [100] or absolute reduction of goblet
cell numbers by apoptosis [111–113].
T h ea p p e a r a n c eo fn e wg o b l e tc e l l si nG C Hm a yb ed u e
to an inhibition of apoptosis. Harris and colleagues [110]
demonstrated increased expression of Bcl-2 in mucous cells
after LPS instillation in Norway rats; Bcl-2 positive mucous
cells decreased to normal levels just prior to resolution of
GCH. In their study, stable overexpression of Bcl-2 increased
LPS-induced GCH compared to wild-type mice [110]. A
similar expression of Bcl-2 and GCH was seen in nasal ep-
ithelium after ozone exposure in rats [114]. Resolution of
GCH may require more than downregulation of Bcl-2: ex-
pression of the proapoptotic mitochondrial regulator Bax,
which can heterodimerize with Bcl-2 and block its function
[115], is associated with the loss of goblet cells in the
resolution phase of GCH, and treatment with agents such
as IFN-γ, which increases Bax expression, is associated with
increased clearance of goblet cells [116], even as treatment
with an anti-Fas antibody fails to clear these cells [113].
Other modulatory pathways such as that coupled to the
epidermalgrowthfactorreceptor(EGFR)alsomaymodulate
GCH induced by either allergen exposure in cultured H292
epithelial cells [117] or Sendai virus exposure in mice [118],Journal of Allergy 7
such that blocking EGFR signaling induced apoptosis in
goblet cells.
These studies serve as one striking example of how
apoptosis may be intimately involved in regulating the phe-
notype and presence of airway epithelial cells in response to
environmental perturbations. Both the appearance and dis-
appearance of goblet cells may require (resp.) inhibition or
initiation of apoptosis. Both oﬀer potential therapeutic
checkpoints to drive the airway mucosa towards a more ho-
meostatic model in response to chronic illness.
7.Apoptosis inAirwayEpitheliuminDisease
Epithelial cell apoptosis is a feature found in damaged and
inﬂamed airways. While increased apoptosis is thought to
contributetoairwaydamageandpathogenesis,itmayalsobe
a consequence of reparative processes that attempt to remove
dead, dying, or damaged cells.
Discussion of epithelial cell apoptosis in airways diseases
is hampered by methodological problems. In addition to
the issues of detachment of apoptotic cells into the airway
lumen and the clearance of apoptotic bodies by professional
phagocytic cells, it can be diﬃcult to distinguish apoptotic
from necrotic cells [14] in airway and lung biopsies. Further,
a measurement of apoptosis at a single time point (e.g.,
via endobronchial biopsy) may not reﬂect either the state
of damage in that airway at that time point, of the disease
state elsewhere in the lung at that time point or of the
course of the disease over time. Repeated measurements of
epithelial cell apoptosis in vivo over time are currently not
possible, as there are no speciﬁc markers to be found in
sputum (noting the recent study of Chimenti et al. [82]
that suggests at least the possibility of identifying TUNEL-
positive epithelial cells in sputum collected from asthmatic
subjects), bronchoalveolar lavage ﬂuid, or exhaled breath
condensate, and repeated biopsy of the airways, in addition
to methodological problems, has obvious limitations in
terms of patient access and risk. The discussion that follows
for each disease then is based on limited in vivo studies
supplemented by mouse and culture models.
7.1. Asthma and Airway Inﬂammation. Asthma has been
recognized since antiquity. The word derives from the Greek
meaning “short of breath.” By the end of the 19th century,
Henry Hyde Salter had recognized the appearance of an
asthmatic airway with inﬂammation and hypertrophy of
smooth muscle [119], and Sir William Osler had described
the relation of allergy, hay fever, familial predisposition,
childhood onset, the presence of Leyden crystals and
Curschmann spirals in sputum, and paroxysms to asthma
[120]. In the early to mid 20th century, asthma was seen
as a disease of intermittent bronchospasm and treated with
various bronchodilators. But from the 1920s, inﬂammation
was recognized as pathogenetic to asthma (for a review see
[121]), and, more recently, the concept of “remodeling”, a
description of a chronically inﬂamed, narrowed asthmatic
airway with smooth muscle hypertrophy, a thickened base-
ment membrane, and—importantly for this discussion—
chronic, persistent, focal to widespread epithelial damage
along with goblet cell hyperplasia [98]—as an end result of
inﬂammation, has deﬁned the disease process [122, 123].
The epithelium is a target of inﬂammatory and physical
insults in both acute asthmatic inﬂammation and in chronic
asthmatic remodeling [1]. Epithelial injury is common even
when the clinical state of asthma is mild [123, 124] and is
persistent over time [1]. Epithelial damage correlates with
airway hyperreactivity and may be seen in newly diagnosed
asthma[125,126].Epithelialdamageismorethanamanifes-
tation of injury: it is an eﬀector of the airway inﬂammation
that marks chronic asthma [127–129]. Epithelial injury leads
to disordered regulation of submucosal myoﬁbroblasts and
ﬁbrinogenesis [130, 131] and release of chemokines such
as IL-8 and eotaxin [132, 133]. Mucosal damage may be
extensive in severe or fatal asthma [134]b u ti sm o r ef o c a l
in mild-moderate asthma [125, 135].
7.1.1. Human Studies. Epithelial cell apoptosis is diﬃcult
to assess in human asthma, both for morphological issues
such as sampling bias and the aforementioned risk of un-
derestimating apoptosis in damaged airways, and issues due
to the variable nature of the disease and variable methods
used to classify patients. Studies of apoptotic markers in
endobronchial biopsies collected from asthmatic subjects
have shown variable results: for example, Vignola et al.
[77] examined TUNEL, Bcl-2, and p53 labeled in a cohort
of asthmatics, either untreated or treated with in-haled or
oral corticosteroid (CS) agents, and in control subjects. In
this study no control subject, and few asthmatic subjects,
had any TUNEL-positive cells in the epithelial layer; while
p53 was not expressed in any group, subjects with asthma,
treated or not, had a higher number of cells labeling for
Bcl-2 versus control. In contrast, a study by Cohen et al.
[89] examined both apoptosis and proliferation in bronchial
biopsies collected from normal subjects and subjects with
mild or severe asthma. In this study, there was a greater
number of TUNEL-positive cells in biopsies of severe
asthmatics compared to controls, along with decreased Bcl-
2 expression and increased proliferation as noted by labeling
for the marker Ki-67. These two studies may be reconciled
on the basis of disease severity, as the Cohen study did not
demonstrateanincreaseinapoptosisinmildasthmatics[89].
Yet another study by Trautmann et al. [53] demonstrated
apoptotic epithelial cells in a small cohort of patients with
mild, persistent asthma, as demonstrated by TUNEL and
Hoechst labeling on endobronchial biopsies. In our own
laboratory, apoptotic epithelial cells can be demonstrated
clearly in endobronchial biopsies of subjects with chronic,
persistent asthma; such labeling is almost never seen in
biopsies collected from normal volunteer subjects (Figure 3).
Therefore, as best can be demonstrated to date, there
are relatively few apoptotic cells present in the airway
epithelium of mild asthmatics; more signiﬁcant apoptosis
and proliferation are seen in asthma and may be related to
both chronicity and severity.
7.1.2. Eﬀect of Corticosteroids. Corticosteroid therapy in
asthma does not necessarily reverse epithelial damage seen in8 Journal of Allergy
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Figure 3: Demonstration of apoptotic airway epithelial cells, as demonstrated by TUNEL stain for single-strand DNA nicking using a
peroxidase method (brown, with hematoxylin counter label), in an endobronchial biopsy of a normal subject (a) and of a subject with
chronic, persistent asthma (b). Note the substantial diﬀerence in the height of the epithelium and the gaps in the epithelium at the basement
membrane between the two biopsies, and the loss of ciliated cells in asthmatic biopsy. The appropriate controls (not shown here) do not
label. Original magniﬁcation, 200x. From the author’s laboratory.
asthma. Corticosteroid treatment clearly suppresses inﬂam-
mation in a large majority of asthmatic patients [136–
139] and in mouse asthma models of allergen-induced
airway inﬂammation [137, 140], though it is clear that
corticosteroids do not alter the natural history of asthma
[139]. In addition to the eﬀects on the number and function
of inﬂammatory cells that ordinarily inﬁltrate the airway
mucosa in chronic asthma, CS treatment also inhibits the
release of inﬂammatory mediators secreted by epithelial cells
such as RANTES [141], GM-CSF [142], and eotaxin [143].
However, the role of corticosteroids on epithelial cell
survival and death is less clear. That some asthmatic subjects
have improved airway mucosal integrity and epithelial cell
anatomyfollowingtreatmentwithinhaledCSisunequivocal:
for some subjects, clinical improvement is accompanied by
evidence of restoration of normal epithelial anatomy as
demonstrated on endobronchial biopsies [144]. Further, CS
treatment of cultured epithelial cells may inhibit cell death
induced by cytokines such as IFN-γ or TGF-β.D e x a m -
ethasone at concentrations of 1mM inhibits IFN-γ induced
cell death in the A549 peripheral lung adenocarcinoma cell
line, perhaps by inducing expression of hIAP [145]. Con-
tradictory reports suggest that TGF-β can induce epithelial
cell apoptosis that is blocked by concurrent treatment with
budesonide [146] orcanpreventepithelial cellapoptosis that
is induced by dexamethasone [147].
Balancing these studies are reports that CS treatment
of cultured human airway epithelial cells and cell lines
may induce apoptosis [50, 147–149]. Either dexamethasone
or budesonide in concentrations of 1–10μMi nc u l t u r e ,a
dose that when adjusted for airway surface area and sol
volume calculates to the high end of the point concen-
tration of an inhaled corticosteroid on epithelium in vivo,
elicits caspase-mediated apoptosis that requires disruption
of mitochondrial polarity and release of cytochrome c [50].
Overexpressing either Bcl-2 or Bcl-xL inhibits CS-induced
apoptosis in this model. A follow-up study demonstrated
that dexamethasone treatment in Balb-c mice for 3 days to
4 weeks also elicited increased epithelial cell apoptosis, as
measured by TUNEL labeling and labeling for the 85kD
fragment of polyadenine ribopolymerase (PARP), a nuclear
enzyme cleaved early in apoptosis [75]. One additional
study also suggests that concurrent treatment of cultured
human airway epithelial cells and cell lines with the beta-
adrenergic agonists albuterol or formoterol can block CS-
induced apoptosis [149]—this may provide one potential
explanation as to why relatively few apoptotic epithelial cells
are seen in the airways of asthmatic subjects, as most of
these subjects receive such agents as part of their antiasthma
controller therapy.
7.1.3. Allergen Exposure, Asthma, and Epithelial Cell Apop-
tosis. Mouse models of airway inﬂammation induced by
exposure to allergen are a time-honored, useful model to
explore the eﬀects of an allergen on airway structure and
function and, unlike in human studies, permit careful
assessment of mechanism and function. The classic model
involves the sensitization and challenge to ovalbumin (OVA)
[150], followed by collection of tissue, BAL ﬂuid, or other
samples at key time points following challenge. Genetic
manipulation of the mouse, adoptive transfer of selected
lymphocytes, or other treatments can modify airway inﬂam-
mation. From these many studies, a clear picture of murine
airway inﬂammation has developed that has informed our
understanding of human airway inﬂammation in asthma.
Two laboratories have demonstrated increased epithelial
cellapoptosisafterOVAchallengeinmice.Truong-Tranetal.
[151] examined apoptosis markers such as caspase-3 activity
in an OVA model in Balb/c mice. Allergen challenge elicited
airway inﬂammation and airway hyperresponsiveness, as
expected, and also an increased number of apoptotic bodies
in the airway mucosa and increased immunolabeling forJournal of Allergy 9
activated caspase-3; both were increased by concurrent
dietary depletion of zinc, a factor that the authors suggest
may be protective against epithelial damage.
A second study from our laboratory [75] examined
epithelial cell apoptosis after OVA challenge with and
without concurrent corticosteroid therapy. This study grew
from an earlier observation (discussed above) that cor-
ticosteroid treatment could induce apoptosis in cultured
primary human airway epithelial cells and cell lines [50]. We
hypothesized that corticosteroids could cause cell death of
airway epithelium in vivo, and the resulting loss of epithelial
cells might explain in part the damage to and denudation
of the airway mucosa in chronic asthma, despite control of
other markers of inﬂammation. To test this, Balb/c mice
were sensitized and challenged to OVA, and both sensitized
mice and control, unsensitized mice were treated at selected
time points with dexamethasone in doses calculated to be at
the high end of a therapeutic regimen for asthma. Allergen
challenge also elicited increased TUNEL and p85-PARP
labeling over the ﬁrst 14 days after challenge, and this was
not decreased by concurrent corticosteroid treatment.
These two papers have made clear the association of
epithelial cell apoptosis and allergen-induced airway inﬂam-
mation. Human studies to examine the association and
to perhaps demonstrate causality of allergen challenge on
epithelial cell apoptosis, however, have not been done to
date. One paper by Robertson et al. [69] examined the
expression of the TNF family mediator TRAIL, which can
induce apoptosis and its receptors DcR2, DR4, and DR5
following segmental allergen challenge by bronchoscopy in a
cohort of asthmatic and nonasthmatic subjects with ragweed
allergy. In asthmatic subjects, instillation of ragweed into the
airways elicited increased epithelial TRAIL labeling within
2 days along with decreased immunostaining of DR4 and
DR5 in eosinophils and macrophages. However, no labeling
ofendobronchialbiopsiestoexamineepithelialcellapoptosis
was done.
7.1.4. Airway Epithelial Cell Damage and Apoptosis in
Response to Exercise and to Cold/Dry Air. A substantial pro-
portion of asthmatic patients demonstrate worsening symp-
tomsandairwayinﬂammationasaresultofexposuretocold,
dehumidiﬁed air associated with exercise [152–154]. Cold
air challenge and hyperpnea both are clinical and laboratory
models used to induce bronchoconstriction in susceptible
subjects with airway hyperreactivity [155, 156]. Athletes,
even those not suspected of having asthma, may also
have airway inﬂammation in response to cold air exposure
[157–159]. Even in more moderate environments such as
swimmingorrowinginwhichthereissubstantialhyperpnea,
elite athletes may have inﬂammatory cells present in induced
sputum and in airway lavage [159, 160]. Airway epithelial
damage in athletes may be seen: for example, in a cohort
of nonasthmatic long-distance runners, increased numbers
of shed bronchial epithelial cells and of TUNEL-positive
apoptotic epithelial cells were seen in induced sputum after a
half-marathon race [82]. These ﬁndings have been explored
in a mechanistic model in mice, in which lung sections
collected from sedentary and endurance-trained mice were
examined [161]. Compared to sedentary mice, the bronchi-
olar epithelium of endurance-trained mice demonstrated a
progressive loss of ciliated cells and both increased apoptosis
andincreasedproliferation,alongwithinﬁltrationofCD45+
leukocytes into the mucosa. These changes may represent an
adaptive response to increased ventilation during exercise.
In summary, asthma, asthma treatment, and Th2-me-
diated airway inﬂammation are associated with central
airway epithelial cell apoptosis. The signiﬁcance of this cell
death is not yet clear, nor is it clear whether epithelial cell
apoptosis represents a compensatory, adaptive response to
clear damaged or dying cells or represents a maladaptive,
pathologic response that over time contributes to the epithe-
lial injury and airways remodeling process that characterizes
chronic asthma.
7.2. Viral and Bacterial Infection. Viral infection of the
airways is increasingly demonstrated as a leading cause of
exacerbations of clinical asthma, particularly in childhood
[162]. Infections with viruses such as adenovirus (AdV),
rhinovirus (RV), respiratory syncytial virus (RSV), inﬂuenza
virus, and parainﬂuenza virus (PIV) occur early in the lower
respiratory tract, are association with exacerbations and
hospitalizations for asthma [163, 164], and are recognized
as an important risk factor in early childhood for the
development of persistent asthma later in life [165, 166].
Patients with asthma with frequent viral-induced exacerba-
tions have worse pulmonary function and a worse clinical
course than patients without such frequent infection [167],
a ﬁnding that may ﬁrst develop in infancy [168]. Frequent
viral infection in infancy may alter Th2 responses [169],
particularly when combined with allergen exposure [170].
Theairwayepitheliumisacentraltargetofviralinfectionand
replication, and epithelial cell damage, release of cytokines,
and other factors. Apoptosis then can be seen as a central
part of host defense; viruses may use apoptosis to subvert
host defense for their own survival. One broad method for
doing so is for a virus to provoke apoptosis of the infected
cell. The potential advantage of this is that it may facilitate
viral egress after replication and thus spreading and survival
of the virus (reviewed in [171]).
Infection with RSV can induce apoptosis in epithelial
cells. This was clearly seen in the study of Kotelkin and
colleagues [172] in which RSV infection of cultured primary
tracheal or small airway epithelial cells, or cell lines, elicited
apoptosis that was associated with both caspase-8 (receptor
mediated type I) and caspase-9 (mitochondrial associated
type II) activation and with expression of both pro- and
antiapoptotic Bcl-2 family members. Interestingly, RSV also
induced TRAIL expression and expression of both the DR4
and DR5 receptors, not seen in normal, uninfected cells.
A more recent study demonstrated that RSV infection was
associated with recovery of soluble TRAIL in airway lavage
ﬂuid and the expression of the TRAIL receptors R1 and
R2 in the airway epithelium of children with RSV infection
and mechanical ventilation [72]. These ﬁndings suggest that
TRAIL may contribute to epithelial injury during severe RSV10 Journal of Allergy
infection. A third study examined the apoptosis-inducing
eﬀect of RSV on primary nasal, tracheal, and bronchial
epithelial cells grown in culture. In this study, RSV elicited
apoptosisthatwasincreasedafterknockdownofendogenous
n e r v eg r o w t hf a c t o r[ 173].
Adenoviral infection also can induce apoptosis in epithe-
lial cells. In a guinea pig model of AdV infection, Singhera
andcolleagues[71]demonstratedincreased,time-dependent
apoptosis, as measured by detection of the p85 fragment of
PARP, along with expression of the DR4 and DR5 receptors.
Interestingly, corticosteroid treatment delayed apoptosis in
cultured epithelial cells following AdV infection and allowed
increased viral particle production. In a chronic infection
model, infection plus sensitization and challenge with oval-
bumin led to increased numbers of apoptotic epithelial cells;
again, corticosteroid treatment decreased the number of
apoptoticcells.Theseexperimentssuggestthatcorticosteroid
use may actually contribute to decreased viral clearance and
thus prolonged infection.
Another virus potentially important to asthma is RV.
While RV infection is less toxic to epithelial cells in diﬀerent
models, it can induce apoptosis via activation of caspase-
9 in cultured, nonpolarized epithelial cells in culture [174].
However, apoptosis was not seen in RV-infected, polarized,
diﬀerentiated epithelial cells, even as RV infection disrupted
the epithelial barrier function as measured by transepithelial
resistance [175].
Inﬂuenza A infection elicits an inﬂammatory airway
response with epithelial cell secretion of cytokines and
chemokines.Onestudyhasexaminedinﬂuenza-A-infection-
induced apoptosis in the H292 human mucoepidermoid
bronchiolar carcinoma cell line. In this study, Brydon et al.
[176] demonstrated that inhibiting apoptosis using caspase
inhibitors increased chemokine secretion, suggesting that
the observed inﬂammatory response in inﬂuenza would
be greater if cell death did not occur. Another study
demonstrated that, in H292 cells, inﬂuenza infection elicited
apoptosis by upregulating mitogen-activated protein kinase
signaling pathways that include c-Jun and p38-MAPK
[177]. The avian H9N2 inﬂuenza virus elicits apoptosis
in primary, polarized, diﬀerentiated airway epithelial cells
with activation of caspase-9 and release of mitochondrial
cytochrome c [178]. In this study, IFN-β was antiviral and
antiapoptotic, which ﬁts the known role of interferons in
blocking viral infection [171]. In this light, a study by Chan
et al. demonstrated that more diﬀerentiated airway epithelial
cells in culture were more resistant to H5N1 inﬂuenza
infection [179]; the authors noted that an undiﬀerentiated
epithelium, as might be seen following damage due to
virus or other agents, could be easily infected. Examining
apoptosis in both undiﬀerentiated or growing epithelial cells
versus a tightly organized diﬀerentiated epithelium with
a highly polarized and tight barrier may be required to
understand how inﬂuenza and other viruses use cell death
to their advantage in clinical infection.
Viral infection also may suppress apoptosis so as to
ensure their replication and survival by preventing the death
of the cell. While cytomegalovirus and certain herpesviruses
are known to inhibit apoptosis (reviewed in [171]), no data
suggest that such suppression occurs after viral infection of
airway epithelium.
Taken together, these studies suggest that infection with
virusesthatcommonlycauserespiratorydiseasesuchasRSV,
AdV, and inﬂuenza elicit apoptosis of airway epithelium. The
interplay between epithelial damage and loss, inﬂammation,
and viral replication is not yet clear from these studies. Stud-
ies are needed to demonstrate whether blocking apoptosis
in viral infection leads to clear changes in the inﬂammatory
state and epithelial damage, and better studies in human
subjects,particularlychildren,areneededtodemonstratethe
association of epithelial cell damage, loss, and apoptosis with
ongoing airway inﬂammation and loss of asthma control.
Though challenging, such studies will provide important
answers as to whether inhibiting apoptosis in the setting of
viral infection leads to better, or worse, clinical outcomes.
7.3. Cystic Fibrosis. Cystic ﬁbrosis (CF) is a multisystem,
genetic disease caused by mutations in the gene encoding
CFTR, which leads to decreased chloride secretion and
increased sodium absorption, with resulting decreases in
lumenal liquid, in airways, the pancreas, and other organs
lined by epithelial cells (reviewed in [180]). In airways, this
leads to dehydration of airway mucous with resulting poor
mucous clearance, infection, particularly with organisms
such as Pseudomonas aeruginosa and Staphylococcus aureus,
inﬂammation, and, over time, bronchiectasis and ﬁbrosis of
the airway [180, 181].
Clearly the epithelium is central to disease pathogenesis
in CF, and airway inﬂammation along with damage to and
loss of epithelial cells are prominent in established bronch-
iectasisandairwayﬁbrosisinthisdisease[182].Overthepast
decade, apoptosis as one of several mechanisms for airway
epithelial cell loss in CF airways has become recognized.
Expression of CD95 and CD95L, along with markers of
apoptosis such as DNA fragmentation, was ﬁrst reported by
Durieu et al. [52] in a study of surgical lung lobectomies
obtained from a small cohort of CF patients. In this study,
CD95L expression was markedly increased in bronchial
epithelial cells, and TUNEL labeling demonstrated apoptotic
cells both in the mucosa and in submucosal gland epithelial
cells. Harris et al. [110] demonstrated increased Bcl-2
presence in airway epithelium in lung blocks collected from
patients with CF compared to normal airways; this was most
prominent in goblet epithelial cells. Bcl-2 expression in this
setting may be a general, compensatory response to permit
survival or may permit preferential development of goblet
cells that then would secrete increased mucous into the CF
airway.
Apoptosis of CF-derived epithelial cells in culture also
has been demonstrated. Ligating CD95 induces apoptosis
(as expected) in normal tracheal epithelial cell lines but in-
creased apoptosis in the CF-derived cell line CFT-2 [183].
The Pseudomonas aeruginosa strain PAO1 induces apoptosis,
as demonstrated by TUNEL labeling, in about 10% of pri-
mary epithelial cells over 8hr of exposure but 50% in
the 9HTEo-transformed cell line that lacks tight junctions
[184]; treating another transformed cell line, 16HBE14o-Journal of Allergy 11
that has high-quality tight junctions, with EGTA made them
more susceptible to PAO1-induced apoptosis. In contrast,
stable transfection of a constitutively active variant of the
regulatoryR-domainofCFTRdidnotalterratesofapoptosis
elicited by PAO1, nor did PAO1 elicit signiﬁcant apoptosis in
cftr −/− mice [184]. These data suggest that the intrinsic loss
ofCFTRislessimportantinepithelialcellsurvivalthanmor-
phologic changes such as barrier integrity. This conclusion is
challenged by a more recent study examining apoptosis after
airborne particulate matter (PM) exposure in two epithelial
cell lines, IB3-1 that contains compound heterozygote delta
F508 and W1282X nonsense CFTR mutations, and S9 that
is derived from the IB3-1 cell line with the CF phenotype
corrected by transfection with wild-type adenoassociated
viral CFTR. Upon exposure to PM in a standard model for
1hr, IB3-1 cells had a rate of apoptosis greater than six
fold higher than that seen in S9 cells; this was associated
with disruption of mitochondrial polarity and activation of
caspase-9 and blocked by overexpression of Bcl-xL [185].
Increased susceptibility to oxidative stress may account for
the eﬀect of PM in this model, and oxidative-stress, a known
inducer of apoptosis in other systems, may also have other
eﬀectsthatinducecelldeathinCFairwayepithelium.Ahmad
and colleagues [186] examined the expression and activity
of sarcoendoplasmic reticulum calcium ATPase (SERCA),
a regulator of calcium homeostasis, in normal and CF
epithelium and tissue. SERCA2 expression was decreased
both in airway biopsies and in diﬀerentiated, polarized
cultured epithelial cells from CF subjects and in CF epithelial
cell lines, and expression of the Δ508-mutated CFTR in cell
lines led to decreased SERCA2 expression. SERCA2 displaces
Bcl-2 from the endoplasmic reticulum [187], and silencing
of the SERCA2 gene enhanced epithelial cell death due to
oxidative stress and to treatment with TNF-α [186].
Pseudomonas infection may also provoke epithelial cell
apoptosis by inducing the expression of cationic innate
host defense peptides that injure the host. One such
cationic peptide is LL-37, the predominant cleavage product
of human cationic antimicrobial peptide (hCAP)-18, the
human cathelicidin (reviewed in [188]). LL-37 is secreted
by both neutrophils and epithelial cells and is upregulated
in response to infection and inﬂammation [188, 189].
Expressing LL-37 in murine lung enhances the clearance of
pulmonary Pseudomonas aeruginosa [190]. LL-37 can induce
apoptosis in both primary cells and in cell lines [191–193]
and does so via activation of the intrinsic pathway with
release of cytochrome c and activation of caspase-9 [193].
Interestingly, in the latter study, cell death required the pres-
ence of both the cationic protein and live bacteria, and either
alone was incapable of inducing apoptosis [193]. The eﬀect
of other cationic proteins such as the eosinophilic cations or
that of synthetic cationic proteins such as polylysine have not
been examined in the context of airway epithelial cell death.
Taken together, these studies show that epithelial cell
apoptosismaybepresentinCFairwaysandthatCFepithelial
cells are perhaps more susceptible to apoptotic cell death
following oxidant stress, bacterial infection, and perhaps to
host defense factors (LL-37 as one demonstrated example).
Therelativecontributionofapoptosistoepithelialdamagein
CF airways, as well as the contribution overall to CF patho-
physiology, is yet to be deﬁned.
7.4.COPD. Chronicobstructivepulmonarydisease(COPD)
arises as a result of the inhalation of noxious stimuli to
the lungs, most commonly cigarette smoke. Damage to the
central airways (chronic bronchitis) and to the peripheral
lung (emphysema) commonly occurs. Several mechanisms
contribute to the pathogenesis of COPD, including inﬂux
of inﬂammatory cells into the lung, disruption of the
balance between proteolytic and antiproteolytic activity, and
oxidative stress [194].
Some recent studies have suggested increased levels of
apoptosis in peripheral lung endothelial cells [195, 196]
and alveolar inﬂammatory cells [197, 198] (also reviewed in
[199]). It is surprising, given the levels of oxidative stress and
the toxins inhaled in cigarette smoke, that apoptosis has not
been investigated rigorously in central airway epithelial cells.
One recent study from Korfei et al. [200] examined markers
of apoptosis in explant tissue obtained from a small cohort
of patients with COPD, idiopathic pulmonary ﬁbrosis, or
donatedlunganddemonstratednoevidenceofsuchmarkers
in COPD. Another study examined the presence of apoptosis
in central airway epithelial cells collected by endobronchial
brushing of 2–4mm airways from 20 normal subjects and 23
subjects with COPD [201]. Several assays to assess apoptosis
were done to minimize the risk of technical artifact skewing
the results. Small airway epithelial cells collected by brushing
from the patients with COPD had increased labeling for the
presence of apoptosis by each assay; this was not aﬀected
by either the age of the subject or by smoking status. A
recent study in which mice were exposed either acutely or
chronically to ozone demonstrated that chronic exposure
led to both central and peripheral airway epithelial cell
apoptosis as measured by immunoreactivity to caspase-3
and the apoptosis protease activating factor-1 (APA-1) [202].
How apoptosis in the more central airways relates to the
genesis of chronic bronchitis or airway inﬂammation is not
yet known.
Peripheral alveolar epithelial cells in smoking subjects
with COPD also show evidence of apoptosis markers such as
p53 [203] or TUNEL [198, 204]. It is interesting to speculate
that such cell death may contribute to the pathogenesis of
emphysema, but no ﬁrm data has emerged.
7.5. Interstitial Lung Disease. Interstitial lung diseases com-
prise a spectrum of illnesses that have at their core ﬁbrotic
damage to the peripheral lung. One of these, idiopathic
pulmonary ﬁbrosis (IPF), is a progressive disease in humans
thathas,ascentraltoitspathogenesis,injurytosmallairways
and alveolar epithelial cells [205, 206]. Over time continued
injury and reaction to injury lead to impaired epithelial
repair, phenotype shifting of ﬁbroblasts to myoﬁbroblasts,
matrix deposition, and scarring. Several types of injuring
agents such as oxidative stress have been postulated as causes
of the initial injury [207], even though antioxidant therapy
has but modest beneﬁt in these patients [208, 209].12 Journal of Allergy
Apoptosis is clearly recognized in the alveolar epithelium
in both human tissue samples of patients with IPF [210, 211]
and in mouse models of lung ﬁbrosis [212, 213]. Increased
expression of Fas [214–216] and of apoptosis signaling
pathway intermediates such as p53 [210, 216, 217]a r es e e n
whichmayhelpexplainthelossofepithelialcells.Incontrast,
damage to and apoptosis of more central airway epithelial
cells are not seen [211].
Centralairwayepithelialcellapoptosisisnotaprominent
feature of other interstitial lung diseases, such as sarcoidosis
or the collagen-vascular-associated lung diseases, as reported
to date.
7.6. Lung Transplantation. Lung transplantation (LT) re-
mains the best hope for selected patients with end-stage lung
diseases. Chronic allograft rejection, clinically manifested as
bronchiolitis obliterans syndrome (BOS) and pathologically
asobliterativebronchiolitis(OB),remainsamajorlimitation
to long-term survival: BOS occurs in 40–60% of lung
transplant recipients within 4 years [218, 219] and is the
leading cause of death after the ﬁrst year [220, 221]. Allograft
rejection is mediated mainly by recipient alloreactive CD4+
and CD8+ eﬀector T lymphocytes [222, 223] developed
against mismatches in HLA class I and II antigens of the
epithelial cells in the allograft [224–226]; these in turn may
be suppressed by regulatory T suppressor lymphocytes that
promote tolerance [227, 228].
There are few reports of epithelial cell apoptosis in the
transplanted human lung. An early study suggested that in
transplanted lungs in which obliterative bronchiolitis was
present, there were increased numbers of TUNEL-positive
cells in large airway, small airway, and alveolar epithelial
cells, whereas such labeling was virtually absent in transplant
lung specimens that had no evidence for OB [229]. An
elegant study of ischemia reperfusion in the transplanted
lung collected samples from peripheral donor lungs during
cold ischemia, warm ischemia, or after graft reperfusion at
the time of implantation. In this study, TUNEL labeling
demonstrated signiﬁcant alveolar but not more central
epithelial cell apoptosis during the time of reperfusion but
not during either ischemia periods [230].
Animal lung transplantation models provide important
data concerning the role of apoptosis in obliterative bronchi-
olitis and in ischemia-reperfusion injury. Increased numbers
of apoptotic epithelial cells are seen prior to sloughing and
obliterative bronchiolitis in the mouse heterotopic tracheal
transplant model [231] and in a similar model in swine
[232], though the degree of apoptosis is modest compared
to the subsequent loss of epithelial cells, suggesting that
other processes such as necrosis or autophagy are as or
moreimportant.Amorerecentstudyexaminesepithelialcell
apoptosis in an orthotopic mouse tracheal transplant model
with preservation of ventilation through the transplanted
airway [233]. In this study, ventilation was permitted or
occluded through the transplanted trachea, and morpho-
metric and immunohistochemical measurements were made
28 days after transplant. Epithelial cell morphology was
betterpreservedintheventilatedgroupwithmorenumerous
ciliated cells, and TUNEL-labeling was substantially less in
these allografts, ∼12%, versus those that were not ventilated,
∼66%. Evidence for obliterative airways disease was present
in the nonventilated allografts suggesting an association
between OB and epithelial cell apoptosis. Other studies
suggest that airway obliteration characteristic of the hetero-
topic tracheal allograft model does not occur in orthotopic
allograftsandthatrecipientepithelialcellsmigratingintothe
donorgraftmayactuallypreventobliteration[234–236].The
role of apoptosis in this process is not known.
One intriguing study examined the role of treatment
with an endothelin-A/B receptor antagonist, SB209670, to
block apoptosis following ischemia-reperfusion injury in a
dog model of lung allotransplantation [237]. Blocking the
endothelin receptors led to lower numbers of apoptotic
epithelial cells in the transplanted peripheral airways and
alveoliasassessedbyTUNELlabeling.Thismaybeduetothe
ability of this antagonist to increase Bcl-2 expression [238].
One paper has examined epithelial cell apoptosis in a
culture model using the KCC-266 cell line; treatment with
an antibody that activates class I HLA responses (W6/32)
elicitsbothproliferationandapoptosisover48to72hr[225].
However,thecelllineisnotcharacterizedordescribedinthis
study or elsewhere, and it is not clear whether this is a central
or alveolar-derived cell.
7.6.1. Environmental Exposures. Environmental agents may
disrupt the integrity and function of the airway epithelium.
In addition to allergen exposure as noted above, various
gasses and particles may elicit damage via initiation of
apoptosis. One group of agents include the incompletely-
combusted components of fossil fuels such as polycyclic
aromatic hydrocarbons (PAHs). One such family of hydro-
carbons, benzo[a]pyrenees, can elicit apoptosis in primary
small airway epithelial cells, but not the peripheral A549
adenocarcinoma epithelial cell line, in culture [239], by
increasing free cytosolic calcium levels [240].
Fine particulate matter also can induce apoptosis in CF-
derived epithelial cells as previously noted [185]. Another
study of the eﬀect of ﬁne particulate matter (PM2.5) on
the L132 human lung epithelial cell line demonstrated
that exposure-induced apoptosis by both receptor-mediated
(caspase-8 activation) and mitochondrial (cytochrome c
release and caspase-9 activation) pathways [241]. These ﬁne
particles are composed of a variety of inorganic and organic
chemicals, including PAHs, and it is not clear which part of
the particle is responsible. To make this more complicated,
another study demonstrated that a water-soluble fraction of
PM2.5 actually inhibits apoptosis induced in three diﬀerent
epithelial cell lines and in primary epithelial cells [242];
the authors suggest that blocking apoptosis may contribute
to prolonged inﬂammation and impaired repair in airways
after pollution exposure. In support of this, Rumelhard
et al. [243] examined the expression and role of EGFR
ligands such as amphiregulin, heparin-binding epidermal
growth factor-like growth factor (HB-EGF), and TGF-α
in primary airway epithelial cells and the 16HBE14o- cell
line after exposure to PM2.5. Secretion of each ligand
was seen, and each elicited expression of cytokines suchJournal of Allergy 13
as granulocyte-macrophage colony stimulating factor (GM-
CSF). This study was subsequently replicated in primary
airway epithelial cells using PM2.5 with diﬀerent PAH and
metal contents, demonstrating signiﬁcant overlap between
the groups suggesting that the exact composition of the
particulate matter is less important [244]. Clearly, the eﬀect
of environmental agents on epithelial cell apoptosis, as well
as the subsequent eﬀect upon airway homeostasis, requires
further investigation.
One interesting paper notes the eﬀect of mechloretham-
ine, a functional analogue of vesicant sulfur mustard used
in chemical warfare, on diﬀerentiated HBE1 cells in culture.
In this model, mechlorethamine treatment elicited epithelial
layer disruption with evidence of both cytotoxic and apop-
toticchangesinaconcentrationandtime-dependentmanner
[245].
8. Conclusions
Apoptosis is an important regulator of epithelial cell survival
in several important clinical diseases. In contrast to inﬂam-
matory cells which undergo apoptosis readily and quickly
after an appropriate stimulus, epithelial cells have some
innate resistance to similar provocation. Understanding this
relative resistance to cell death may hold a vital clue for
understanding the role of apoptosis in airway homeostasis
and may also have important implications for diseases that
are epithelial based but not touched on in this paper, such
as lung cancer. While this paper has not considered the roles
of necrosis and autophagy in epithelial cell death, the former
especially may be as, or more, important in selected airway
conditions. Nevertheless, apoptosis clearly is involved in
epithelial cell death in several inﬂammatory airways diseases.
There is regional variation in the response to apoptotic
stimuli: when directly assessed, small airways (bronchiolar)
epithelial cells are more sensitive than those collected from
larger bronchi or trachea. There is signiﬁcant variation in
the response to activation of death receptors and in receptor-
mediated versus stress-activated (via mitochondrial polarity
disruption) apoptosis. Again, the reasons for this are not
understood.
Finally, apoptosis is required to return an inﬂamed air-
way, or one that is hyperplastic or metaplastic, to normalcy.
The controlling mechanisms by which this occurs are still
not understood. Recognizing when and how apoptosis is
important to airway inﬂammation and how to turn that
process to our advantage oﬀers potential therapeutic targets
for several airways diseases.
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